Drug Profile
Research programme: neuroprotective therapies - BMS
Alternative Names: BMS 554216Latest Information Update: 17 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Indoles
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Spinal cord injuries; Stroke
Most Recent Events
- 17 Jan 2008 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
- 17 Jan 2008 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 16 Aug 2004 Preclinical trials in Spinal cord injuries in USA (unspecified route)